EMAT
Combination Post-transplant Consolidation Therapy With Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients With Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 31 patients (estimated)
- Sponsors
- Medical College of Wisconsin
- Tags
- Monoclonal Antibody, CD38, Minimal Residual Disease (MRD)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1902
- NCT Identifier
- NCT05690984
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.